UBS: BOSIDENG (03998) Recommended to "Buy" with a target price of 5.92 Hong Kong dollars.
UBS expects the average annual growth rate of net income for Bosideng in the fiscal year 2025 to 2026 to be 13%.
UBS released a research report stating that they have given a "buy" rating to BOSIDENG (03998), believing that the valuation is attractive and expecting a net income annual growth rate of 13% for the fiscal years 2025 to 2026, with a dividend yield of 7%. Despite its higher growth potential, the current trading price is still below the industry median, with a target price of 5.92 Hong Kong dollars.
The bank expressed optimism about BOSIDENG's diversified business strategy, which includes outdoor and sun protection products aimed at capturing sales growth in the summer and autumn in the long term. They expect this strategy to enhance the company's profit stability, reduce its dependence on winter, and potentially lead to a revaluation. In addition, the bank believes upcoming catalysts for the company include its performance in the first half of the 2025 fiscal year, the tourism boom in Harbin, and new product releases.
Related Articles

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025